Special Issue

Molecular Cancer Therapeutics

Submission Deadline: May 01, 2019 (Closed)

Guest Editor

Tapan K Bera, PhD

Senior Associate Scientist, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA

Website | E-Mail

Research Interests: antibody engineering; immunotherapy; recombinant immunotoxin; multiple myeloma; BCMA; mesothelin

About This Topic

Molecular Cancer Therapeutics is a special issue focused on articles related to the molecular basis of cancer, discovery and preclinical development of novel therapeutic agents for cancer and preclinical studies of approved therapeutics. Those includes identification of new genes that are specifically expressed in cancer, targeted therapy of cancer, the immunotherapy, and the study of small molecule and protein drugs. In this special issue of OBM Genetics, we aim to the introduction of the latest research progress and novel models and technologies in molecular cancer therapeutics. There is no limitation on the article types, original research papers, reviews, editorial, short communications, case reports and perspectives are welcome for submission. We sincerely welcome authors in this field to contribute their excellent works to this exciting forum.

Planed Papers

Title: Antibody-drug conjugates to treat negative breast cancer
Author: X. Margaret Liu

Title: Cardiomyocytes and the changes of the fuctionally determined spatial organization of ryanodin receptors during tumorgenesis
Author: Michael Hausmann

Title: IGF2 in physiology, cancer and cancer treatment
Author: Karoly Szuhai

Title: Clinical and molecular characteristics of biliary tract carcinoma using next-generation sequencing
Author: Antonio Cubillo Gracian

Title: Current progress on cancer immunotherapies using small molecules targeting PD-L1 stability
Author: Xiaolong Yang

Title: Interplay of Oncogenes and Their Immunosuppression in Gastric Cancer
Authors: Jiankang Jin, Xiaodan Yao, Shumei Song^* and Jaffer A. Ajani^*

Title: The use of Molecular techniques in diagnosis and therapy for patients
Author: Lampri Evangeli, et al

Title: A study on some calixpyrrole derivatives as potential cancer drugs
Authors: Franz Heinrich Kohnke, Camillo Rosano

Manuscript Submission Information

Manuscripts should be submitted through the LIDSEN Submission System. Detailed information on manuscript preparation and submission is available in the Instructions for Authors. All submitted articles will be thoroughly refereed through a single-blind peer-review process and will be processed following the Editorial Process and Quality Control policy. Upon acceptance, the article will be immediately published in a regular issue of the journal and will be listed together on the special issue website, with a label that the article belongs to the Special Issue. LIDSEN distributes articles under the Creative Commons Attribution (CC BY 4.0) License in an open-access model. The authors own the copyright to the article, and the article can be free to access, distribute, and reuse provided that the original work is correctly cited.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). Research articles and review articles are highly invited. Authors are encouraged to send the tentative title and abstract of the planned paper to the Editorial Office (genetics@lidsen.com) for record. If you have any questions, please do not hesitate to contact the Editorial Office.

Welcome your submission!

Publication

Open Access Review Molecular Mechanisms of Feline Cancers by Jessica Lin  , Valentina L Kouznetsova  and Igor F Tsigelny Received: 08 December 2020;  Published: 24 May 2021;  doi: 10.21926/obm.genet.2102131 Abstract Feline cancers have not been studied as extensively as canine cancers, though they may offer similar advantages, with cats being immunocompetent animals subject to similar conditions as their human counterparts. The most common feline cancers include lymphoma, squamous cell carcinoma, sarcoma, and mammary tumors, though mast cell tumors were [...]

Open Access Original Research Role of DNA Damage and MMP Loss in Radiosensitization-Induced Apoptosis by Ellagic Acid in HeLa Cells by Vidhula R Ahire  , Amit Kumar  , Sushma Bhosle  and Kaushala Prasad Mishra Received: 22 September 2020;  Published: 14 May 2021;  doi: 10.21926/obm.genet.2102129 Abstract Ellagic acid (EA) is a polyphenol found in grapes, pomegranates, walnuts, etc. exhibits anti-cancer properties. The current study was conducted to understand the radiosensitizing role of EA on HeLa cells. Monotherapy of EA and radiation was initially studied on HeLa cells. The addition of EA before the radiation treatment subsequently made [...]

Open Access Review Current Progress in Cancer Immunotherapies Using Small Molecules Targeting PD-L1 Stability by Macyn Leung  , Alexander Pipchuk  and Xiaolong Yang Received: 11 January 2021;  Published: 24 March 2021;  doi: 10.21926/obm.genet.2101127 Abstract PD-L1 is an immune checkpoint protein that is frequently overexpressed by the cells in the tumor microenvironment. PD-L1 binds to PD-1 present on the activated antitumor T-cells, which allows for tumor immune escape. The ability of the PD-1/PD-L1 axis to suppress antitumor immunity enables its application as a potential target for small-molecu [...]

Open Access Review Oncogenes Orchestrate Immunosuppressive Stroma in Gastric Adenocarcinoma by Jiankang Jin  , Shumei Song  and Jaffer A. Ajani Received: 30 June 2020;  Published: 16 September 2020;  doi: 10.21926/obm.genet.2003116 Abstract Gastric adenocarcinoma (GAC) is among the three most common cancers in the world. The majority of GAC patients are diagnosed in an advanced stage and have a median survival of ~9 months. There are limited effective therapeutic strategies available in the clinic and currently U.S. Food and Drug Administration (FDA) approved immune therapy is [...]

Open Access Review Detection of Circulating Tumor DNA in Solid Tumors by Ugo Testa  , Germana Castelli  and Elvira Pelosi Received: 27 May 2020;  Published: 06 August 2020;  doi: 10.21926/obm.genet.2003114 Abstract Cancer is characterized by sequential and progressive genetic and epigenetic alterations in key proto-oncogenes and tumor suppressor genes, which ultimately lead to tumor development. Advances in the technology of analysis of molecular mechanisms have increased the efficiency of clinical management of cancer patients. Recent years have witness [...]

Open Access Communication Effective Delivery of Cancer Vaccines with Oxidatively Photo-Inactivated Transgenic Leishmania for Tumor Immunotherapy in Mouse Models by Kwang Poo Chang  , Dennis K.P. Ng  , Chia-Kwung Fan  , Ramesh B. Batchu  and Bala K. Kolli Received: 29 December 2019;  Published: 24 February 2020;  doi: 10.21926/obm.genet.2001103 Abstract The parasitic protozoa in the genus of Leishmania have exceptionally favorable attributes for exploitation as a vehicle for safe and effective delivery of transgenically incorporated vaccines against infectious and malignant diseases. A dual suicidal mechanism was installed in Leishmania via genetic [...]

Open Access Review Insulin-Like Growth Factor 2 in Physiology, Cancer, and Cancer Treatment by Bas T Röttgering  and Karoly Szuhai Received: 14 May 2019;  Published: 14 October 2019;  doi: 10.21926/obm.genet.1904096 Abstract Insulin-like growth factor 2 (IGF2) is a strong mitogenic peptide with an imprinted gene that is primarily involved in fetal development. It is highly expressed in the fetus where it is involved in fetal growth and tissue differentiation. However, postnatally, the expression of IGF2 decreases despite higher expression levels in the blood as [...]

Open Access Communication Upregulation of COX-2 in MCF7 Breast Cancer Cells When Exposed to Shear Stress by Caymen M. Novak  , Eric N. Horst  , Shreya Raghavan  and Geeta Mehta Received: 17 June 2019;  Published: 06 September 2019;  doi: 10.21926/obm.genet.1903092 Abstract Background: Invasive breast cancer affects 1 in 8 women in the United States and causes one of the highest cancer mortality rates for women. Cyclooxygenase-2 (COX-2), a central enzyme in prostaglandin biosynthesis, is implicated in breast cancer initiation, progression, invasion, and metast [...]

Open Access Research Article BSA-Embedded Carbonate Apatite Enhances Chemotherapeutic Effect of Paclitaxel in vitro and in vivo by Tahereh Fatemian  and Ezharul Hoque Chowdhury Received: 29 March 2019;  Published: 15 August 2019;  doi: 10.21926/obm.genet.1903090 Abstract Introduction of biocompatible ingredients into nano-material formulations has been studied as a strategy for the enhancement of the pharmacokinetics as well as pharmacodynamics of the final product. With the aim of enhancing drug loading and the ultimate efficacy, incorporation of Bovine Serum Albumin (BSA) into carbonate apatite (CA) nanopart [...]

Open Access Review Molecular Mechanisms of Canine Cancers by Jennie Cao  , Valentina L Kouznetsova  and Igor F Tsigelny Received: 30 January 2019;  Published: 01 April 2019;  doi: 10.21926/obm.genet.1902071 Abstract Cancer is the leading cause of death in dogs, and 50 percent of dogs over the age of 10 develop cancer at some point. The most common cancers in dogs include lymphoma, mast cell tumors, osteosarcoma, mammary gland tumors, and melanoma, and many of them share marked similarities with their human counterparts. Although canines are afflicted [...]